TRAVERE THERAPEUTICS INC (TVTX) — insider trading
Health Care · NASDAQ
TRAVERE THERAPEUTICS INC (TVTX) has 223 reported SEC Form 4 insider transactions in our data, including 47 open-market sales among the most recent 100 (latest 2026-09-17).
Recent Form 4 transactions
Showing the 100 most recent of 223 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion (derivative) | 8,282 | — | $0 | Form 4 |
| 2026-09-17 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Open-market sale | 8,282 | $65.07 | $538.9K | Form 4 |
| 2026-09-17 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion | 8,282 | $22.40 | $185.5K | Form 4 |
| 2026-09-17 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Option exercise / conversion (derivative) | 108,493 | — | $0 | Form 4 |
| 2026-09-17 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 6,802 | $64.95 | $441.8K | Form 4 |
| 2026-09-17 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 101,691 | $64.59 | $6.57M | Form 4 |
| 2026-09-17 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Option exercise / conversion | 108,493 | $23.34 | $2.53M | Form 4 |
| 2026-09-16 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Option exercise / conversion (derivative) | 57,500 | — | $0 | Form 4 |
| 2026-09-16 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Option exercise / conversion (derivative) | 55,000 | — | $0 | Form 4 |
| 2026-09-16 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Option exercise / conversion (derivative) | 350 | — | $0 | Form 4 |
| 2026-09-16 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Open-market sale | 47,746 | $63.61 | $3.04M | Form 4 |
| 2026-09-16 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Open-market sale | 65,104 | $63.12 | $4.11M | Form 4 |
| 2026-09-16 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Option exercise / conversion | 57,500 | $26.88 | $1.55M | Form 4 |
| 2026-09-16 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Option exercise / conversion | 55,000 | $15.46 | $850.3K | Form 4 |
| 2026-09-16 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Option exercise / conversion | 350 | $17.96 | $6.3K | Form 4 |
| 2026-09-16 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion (derivative) | 17,717 | — | $0 | Form 4 |
| 2026-09-16 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion (derivative) | 55,000 | — | $0 | Form 4 |
| 2026-09-16 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-09-16 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Open-market sale | 79,113 | $63.65 | $5.04M | Form 4 |
| 2026-09-16 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Open-market sale | 93,604 | $63.25 | $5.92M | Form 4 |
| 2026-09-16 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion | 17,717 | $26.88 | $476.2K | Form 4 |
| 2026-09-16 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion | 55,000 | $15.46 | $850.3K | Form 4 |
| 2026-09-16 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion | 100,000 | $11.25 | $1.13M | Form 4 |
| 2026-09-16 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Option exercise / conversion (derivative) | 195,841 | — | $0 | Form 4 |
| 2026-09-16 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 96,125 | $63.64 | $6.12M | Form 4 |
| 2026-09-16 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 99,716 | $63.26 | $6.31M | Form 4 |
| 2026-09-16 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Option exercise / conversion | 195,841 | $23.34 | $4.57M | Form 4 |
| 2026-09-15 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Option exercise / conversion (derivative) | 39,650 | — | $0 | Form 4 |
| 2026-09-15 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Option exercise / conversion (derivative) | 39,000 | — | $0 | Form 4 |
| 2026-09-15 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Open-market sale | 270 | $65.31 | $17.6K | Form 4 |
| 2026-09-15 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Open-market sale | 3,000 | $63.65 | $191.0K | Form 4 |
| 2026-09-15 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Open-market sale | 29,021 | $62.66 | $1.82M | Form 4 |
| 2026-09-15 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Open-market sale | 63,907 | $61.99 | $3.96M | Form 4 |
| 2026-09-15 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Option exercise / conversion | 39,650 | $17.96 | $712.1K | Form 4 |
| 2026-09-15 | ROTE WILLIAM E. | Officer (Chief Research Officer) | Option exercise / conversion | 39,000 | $25.25 | $984.8K | Form 4 |
| 2026-09-15 | REED ELIZABETH E | Officer (Chief Legal Officer and GC) | Option exercise / conversion (derivative) | 37,500 | — | $0 | Form 4 |
| 2026-09-15 | REED ELIZABETH E | Officer (Chief Legal Officer and GC) | Open-market sale | 300 | $65.31 | $19.6K | Form 4 |
| 2026-09-15 | REED ELIZABETH E | Officer (Chief Legal Officer and GC) | Open-market sale | 1,400 | $63.69 | $89.2K | Form 4 |
| 2026-09-15 | REED ELIZABETH E | Officer (Chief Legal Officer and GC) | Open-market sale | 13,874 | $62.63 | $869.0K | Form 4 |
| 2026-09-15 | REED ELIZABETH E | Officer (Chief Legal Officer and GC) | Open-market sale | 21,926 | $62.03 | $1.36M | Form 4 |
| 2026-09-15 | REED ELIZABETH E | Officer (Chief Legal Officer and GC) | Option exercise / conversion | 37,500 | $15.46 | $579.8K | Form 4 |
| 2026-09-15 | Inrig Jula | Officer (EVP, Head of R&D & CMO) | Option exercise / conversion (derivative) | 32,395 | — | $0 | Form 4 |
| 2026-09-15 | Inrig Jula | Officer (EVP, Head of R&D & CMO) | Open-market sale | 400 | $65.31 | $26.1K | Form 4 |
| 2026-09-15 | Inrig Jula | Officer (EVP, Head of R&D & CMO) | Open-market sale | 1,600 | $63.69 | $101.9K | Form 4 |
| 2026-09-15 | Inrig Jula | Officer (EVP, Head of R&D & CMO) | Open-market sale | 17,284 | $62.62 | $1.08M | Form 4 |
| 2026-09-15 | Inrig Jula | Officer (EVP, Head of R&D & CMO) | Open-market sale | 25,390 | $62.02 | $1.57M | Form 4 |
| 2026-09-15 | Inrig Jula | Officer (EVP, Head of R&D & CMO) | Option exercise / conversion | 32,395 | $8.93 | $289.3K | Form 4 |
| 2026-09-15 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion (derivative) | 36,526 | — | $0 | Form 4 |
| 2026-09-15 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion (derivative) | 1,381 | — | $0 | Form 4 |
| 2026-09-15 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion (derivative) | 39,283 | — | $0 | Form 4 |
| 2026-09-15 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Open-market sale | 1,431 | $65.31 | $93.5K | Form 4 |
| 2026-09-15 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Open-market sale | 1,400 | $63.65 | $89.1K | Form 4 |
| 2026-09-15 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Open-market sale | 27,421 | $62.59 | $1.72M | Form 4 |
| 2026-09-15 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Open-market sale | 71,938 | $62.05 | $4.46M | Form 4 |
| 2026-09-15 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion | 36,526 | $8.93 | $326.2K | Form 4 |
| 2026-09-15 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion | 1,381 | $22.40 | $30.9K | Form 4 |
| 2026-09-15 | Heerma Peter | Officer (EVP, CHIEF COMMERCIAL OFFICER) | Option exercise / conversion | 39,283 | $26.88 | $1.06M | Form 4 |
| 2026-09-15 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Option exercise / conversion (derivative) | 95,666 | — | $0 | Form 4 |
| 2026-09-15 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 270 | $65.31 | $17.6K | Form 4 |
| 2026-09-15 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 3,102 | $63.64 | $197.4K | Form 4 |
| 2026-09-15 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 28,796 | $62.66 | $1.80M | Form 4 |
| 2026-09-15 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Open-market sale | 63,498 | $61.99 | $3.94M | Form 4 |
| 2026-09-15 | Dube Eric M | Director, Officer (CHIEF EXECUTIVE OFFICER) | Option exercise / conversion | 95,666 | $23.34 | $2.23M | Form 4 |
| 2026-09-15 | Cline Christopher R. | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-09-15 | Cline Christopher R. | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 400 | $65.31 | $26.1K | Form 4 |
| 2026-09-15 | Cline Christopher R. | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 1,900 | $63.69 | $121.0K | Form 4 |
| 2026-09-15 | Cline Christopher R. | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 20,735 | $62.61 | $1.30M | Form 4 |
| 2026-09-15 | Cline Christopher R. | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 27,473 | $62.00 | $1.70M | Form 4 |
| 2026-09-15 | Cline Christopher R. | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion | 20,000 | $17.44 | $348.8K | Form 4 |
| 2026-09-15 | Calvin Sandra | Officer (SVP, CHIEF ACCOUNTING OFFICER) | Option exercise / conversion (derivative) | 1,625 | — | $0 | Form 4 |
| 2026-09-15 | Calvin Sandra | Officer (SVP, CHIEF ACCOUNTING OFFICER) | Option exercise / conversion (derivative) | 1,250 | — | $0 | Form 4 |
| 2026-09-15 | Calvin Sandra | Officer (SVP, CHIEF ACCOUNTING OFFICER) | Option exercise / conversion (derivative) | 2,500 | — | $0 | Form 4 |
| 2026-09-15 | Calvin Sandra | Officer (SVP, CHIEF ACCOUNTING OFFICER) | Open-market sale | 300 | $63.66 | $19.1K | Form 4 |
| 2026-09-15 | Calvin Sandra | Officer (SVP, CHIEF ACCOUNTING OFFICER) | Open-market sale | 800 | $62.85 | $50.3K | Form 4 |
| 2026-09-15 | Calvin Sandra | Officer (SVP, CHIEF ACCOUNTING OFFICER) | Open-market sale | 4,275 | $62.14 | $265.6K | Form 4 |
| 2026-09-15 | Calvin Sandra | Officer (SVP, CHIEF ACCOUNTING OFFICER) | Option exercise / conversion | 1,625 | $20.46 | $33.2K | Form 4 |
| 2026-09-15 | Calvin Sandra | Officer (SVP, CHIEF ACCOUNTING OFFICER) | Option exercise / conversion | 1,250 | $22.40 | $28.0K | Form 4 |
| 2026-09-15 | Calvin Sandra | Officer (SVP, CHIEF ACCOUNTING OFFICER) | Option exercise / conversion | 2,500 | $27.50 | $68.8K | Form 4 |
| 2026-09-10 | Meckler Jeffrey A | Director | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-09-10 | Meckler Jeffrey A | Director | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-09-10 | Meckler Jeffrey A | Director | Open-market sale | 3,100 | $68.09 | $211.1K | Form 4 |
| 2026-09-10 | Meckler Jeffrey A | Director | Open-market sale | 14,000 | $67.46 | $944.5K | Form 4 |
| 2026-09-10 | Meckler Jeffrey A | Director | Open-market sale | 1,200 | $66.15 | $79.4K | Form 4 |
| 2026-09-10 | Meckler Jeffrey A | Director | Open-market sale | 1,700 | $65.39 | $111.2K | Form 4 |
| 2026-09-10 | Meckler Jeffrey A | Director | Option exercise / conversion | 10,000 | $26.52 | $265.2K | Form 4 |
| 2026-09-10 | Meckler Jeffrey A | Director | Option exercise / conversion | 10,000 | $17.44 | $174.4K | Form 4 |
| 2026-09-02 | Cline Christopher R. | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 642 | $66.37 | $42.6K | Form 4 |
| 2026-08-18 | LYONS GARY A | Director | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-08-18 | LYONS GARY A | Director | Open-market sale | 900 | $63.86 | $57.5K | Form 4 |
| 2026-08-18 | LYONS GARY A | Director | Open-market sale | 4,100 | $63.27 | $259.4K | Form 4 |
| 2026-08-18 | LYONS GARY A | Director | Option exercise / conversion | 5,000 | $17.44 | $87.2K | Form 4 |
| 2026-08-17 | LYONS GARY A | Director | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-08-17 | LYONS GARY A | Director | Open-market sale | 500 | $64.16 | $32.1K | Form 4 |
| 2026-08-17 | LYONS GARY A | Director | Open-market sale | 2,600 | $63.50 | $165.1K | Form 4 |
| 2026-08-17 | LYONS GARY A | Director | Open-market sale | 1,900 | $62.53 | $118.8K | Form 4 |
| 2026-08-17 | LYONS GARY A | Director | Option exercise / conversion | 5,000 | $17.44 | $87.2K | Form 4 |
| 2026-06-22 | Inrig Jula | Officer (CHIEF MEDICAL OFFICER) | Bona fide gift | 468 | — | $0 | Form 4 |
| 2026-06-12 | Baynes Roy D. | Director | Option exercise / conversion (derivative) | 4,500 | — | $0 | Form 4 |
| 2026-06-12 | Baynes Roy D. | Director | Open-market sale | 4,500 | $50.00 | $225.0K | Form 4 |
| 2026-06-12 | Baynes Roy D. | Director | Option exercise / conversion | 4,500 | $21.38 | $96.2K | Form 4 |
Ask the chat about TVTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: TRAVERE THERAPEUTICS INC (TVTX).
Last updated 2026-09-17 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.